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Deficiency in PTEN (phosphatase and tensin homolog deleted on
chromosome 10) is the underlying cause of PTEN hamartoma
tumor syndrome and a wide variety of human cancers. In skin
epidermis, we have previously identified an autocrine FGF signal-
ing induced by loss of Pten in keratinocytes. In this study, we
demonstrate that skin hyperplasia requires FGF receptor adaptor
protein Frs2α and tyrosine phosphatase Shp2, two upstream reg-
ulators of Ras signaling. Although the PI3-kinase regulatory sub-
units p85α and p85β are dispensable, the PI3-kinase catalytic
subunit p110α requires interaction with Ras to promote hyperpla-
sia in Pten-deficient skin, thus demonstrating an important cross-
talk between Ras and PI3K pathways. Furthermore, genetic and
pharmacological inhibition of Ras–MAPK pathway impeded epi-
dermal hyperplasia in Pten animals. These results reveal a positive
feedback loop connecting Pten and Ras pathways and suggest that
FGF-activated Ras–MAPK pathway is an effective therapeutic tar-
get for preventing skin tumor induced by aberrant Pten signaling.
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As a commonly mutated tumor suppressor gene, PTEN(phosphatase and tensin homolog deleted on chromosome
10) plays critical roles in tissue homeostasis and cancer develop-
ment (1). In PTEN hamartoma tumor syndrome (PHTS), germ-
line mutations of PTEN cause hyperplastic changes in the skin,
which manifest into acral keratosis and papilloma (2). Although
somatic mutation of PTEN is rare in skin lesions, the majority of
human actinic keratosis and squamous cell carcinoma (SCC) of
the skin exhibited reduced levels of PTEN, suggesting that epi-
genetic or posttranscriptional down-regulation of PTEN is an
important risk factor in skin tumorigenesis (3–5). Consistent with
this, genetic ablation of Pten in mouse models readily leads to skin
hyperkeratosis, papilloma, and eventually SCC (6–8).
FGF signaling has both pro- and antitumorigenic functions in
the skin. Aged animals lacking Fgfr2b in the epidermis displayed
thickening in the skin and heightened sensitivity to a chemical
carcinogen, whereas overexpression of Fgf7 or Fgf10, two cognate
ligands of Fgfr2b, resulted in epidermal hyperplasia and tumor
formation (9, 10). Paracrine FGFR2 signaling has also been
found to be important in mediating the oncogenic activity of p63,
which is frequently amplified in SCC (11). We recently identified
a critical link between Pten and FGF signaling, showing that el-
evated PI3K signaling in Pten-deficient epidermis led to a mam-
malian target of rapamycin (mTOR)-regulated increase in Fgf10
translation (4). The resulting Fgf10–Fgfr2 signaling in the epi-
dermis was both necessary and sufficient to promote skin tu-
morigenesis. Interestingly, activating mutations in FGFR3 and
PIK3CA, which encode the catalytic subunit of PI3 kinase, have
been identified in epidermal nevi and seborrheic keratosis (12,
13). Although these skin lesions have different pathologies from
papillomas and SCCs, all of them share the epidermal hyperplasia
phenotype. These observations suggest that FGFR and PI3K sig-
naling are intimately connected in human skin tumorigenesis.
How FGF signaling promotes skin tumorigenesis is not well
understood (14). A myriad of cytoplasmic proteins have been
implicated in mediating FGF downstream signaling (15). The
most important among them is adaptor protein Frs2, which can
activate Ras signaling by recruiting Grb2 and tyrosine phospha-
tases Shp2. In addition, Gab1 protein can stimulate PI3K signal-
ing by direct binding to a PI3K regulatory subunit, and PLCγ
proteins can induce PKC signaling. Adding to the complexity of
the FGF signaling network, there is extensive cross-talk among its
downstream pathways. For example, Ras protein can directly bind
and activate PIK3CA (16). Conversely, some studies indicate that
PI3K-activated AKT may also phosphorylate Ras downstream
effector Raf to suppress its activity (17, 18). Interestingly, it has
been observed that 7,12-Dimethylbenz[a]anthracene (DMBA)-
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin carci-
nomas in Pten heterozygous mice exhibit eitherH-ras activation or
a complete loss of Pten alleles, but not both (19). The underlying
cause for such mutual exclusivity between Ras and Pten mutations
in skin cancer remains unsolved.
In this study, we took a genetic approach to dissect FGF
downstream pathways in skin tumorigenesis. Our results show
that Pten-deficient skin requires Frs2 and Shp2, suggesting that
Frs2/Shp2-activated Ras signaling may be the critical downstream
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effector of FGF signaling. In support of this, although deletion of
the p85 regulatory subunit of PI3K had no effect, disruption of
the Ras interaction with the p110α catalytic subunit of PI3K
suppressed skin hyperplasia. Furthermore, genetic ablation of the
Raf–Mek–Erk signaling cascade blocked tumorigenesis in Pten-
deficient epidermis. These results show that Ras signaling both
enhances PI3K activity to cooperate with Pten deletion and also
promotes skin hyperplasia by activating the MAPK pathway. Finally,
we found that pharmacological inhibition of Erk was sufficient to
prevent and even to reverse epidermal hyperplasia induced by Pten
deletion. These results demonstrate that targeting of MAPK sig-
naling is an effective approach to treat Pten-deficient skin lesion.
Results
Frs2α and Shp2 Convey FGF Signaling in Pten-Deficient Epidermis.
Previous studies have established that epidermal deletion of Pten
in mouse results in skin lesions that closely mimic human PTHS
and the onset of SCC (6–8). Using the Le-Cre driver to target
keratinocytes in the cheek and the eyelid, we observed similar
epidermal hyperplasia in 1-mo-old Le-Cre;Ptenflox/flox (PtenCKO)
animals (Fig. 1A). Analysis of this mouse model demonstrated
that loss of Pten led to increasing expression of Fgf10 in kera-
tinocytes, which activated Fgfr2 in an autocrine loop to promote
skin tumorigenesis (4). To further determine the mediators of
FGF signaling in Pten-deficient skin tumor, we genetically ab-
lated the adapter protein Frs2α, the predominantly expressed
Frs2 family member, in skin epidermis (Fig. S1A) (20). Histo-
logical analysis showed that deletion of Frs2α alone did not cause
overt skin abnormality, but the epidermal hyperplasia phenotype
was completely suppressed in PtenCKO;Frs2αCKO animals (Fig. 1A
and Fig. S1 B and C). Unlike PtenCKO animals that exhibit sig-
nificant expansions in both the K14+ basal layer and the K10+
suprabasal layer in the epidermis, these two keratinocyte layers in
PtenCKO;Frs2αCKO remained unchanged compared with those of
control animals. Consistent with abrogation of the hyperplasia
phenotype, the proliferation marker Ki-67 and basal epidermis
marker ΔNp63 in PtenCKO;Frs2αCKO skin also reverted to the wild-
type levels. By immunostaining and Western blot analysis, how-
ever, we showed that pAKT, pS6, and p4EBP1 levels remained
elevated, reflecting the up-regulation of PI3K signaling induced by
Pten deletion (Fig. 1 and Fig. S1D). As a result, we still observed
increased Fgf10 expression in PtenCKO;Frs2αCKO skin epidermis
(Fig. 1 and Fig. S1E). We recently showed that FGF signaling
requires cooperation between Frs2α and Shp2 to activate Ras
signaling in eye development (21, 22). This genetic pathway is
apparently conserved in skin lesion, as PtenCKO;Shp2CKO also lacks
the epidermal hyperplasia phenotype despite elevated levels of
PI3K activity and Fgf10 expression (Fig. 1 and Fig. S1D). These
results suggested that Frs2α and Shp2 are essential components
of the Pten–FGF signaling axis in skin hyperplasia.
Ras Binding to p110α Enhances PI3K Signaling. Ras is the down-
stream target of Frs2α and Shp2, and it is also known to interact
with PI3 kinase (23). The PI3 kinase consists of two subunits: a
regulatory subunit p85, which can be directly stimulated by re-
ceptor tyrosine kinases, and a catalytic subunit p110, responsible
for lipid phosphorylation. Importantly, the p110α subunit also
contains a Ras-binding domain (RBD), which has been shown to
be required for Ras-induced transformation in multiple types of
cancers (23). To examine PI3K signaling in the epidermis, we
generated a conditional knockout of p85α and p85β, the two
major regulatory subunits of PI3 kinase (24). Surprisingly, we still
observed significant facial swelling in adult Le-Cre;Ptenflox/flox;
p85αflox/flox;p85βKO/KO (PtenCKO;p85CKO) animals (Fig. S2). This
is confirmed by histological analysis, which showed similar expan-
sion of the epidermal layers in PtenCKO and PtenCKO;p85CKO skin.
Because p85α and p85β subunits of PI3 kinase were dispens-
able for Pten-depleted skin lesion, we next considered whether
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Fig. 1. Frs2α and Shp2 mediate FGF signaling in Pten-null epidermis.
(A) Phenotypic comparison of facial skin in Le-Cre, PtenCKO, PtenCKO;Frs2α CKO,
and PtenCKO;Shp2 CKOmice. Rescue of the hyperplasia phenotype was evident in
PtenCKO;Frs2α CKO and PtenCKO;Shp2 CKO mice, as shown by H&E and immu-
nostaining for K14/K10, Ki-67, ΔNp63, and Fgf10 on transverse sections of facial
skin. Arrows point to Ki-67
+ cells in the epidermis. Note that pAKT and Fgf10
remained elevated in both mutants. (Scale bars, 50 μm.) (Magnification, Insets:
3×.) (B) Immunoblotting analyses showed that expression of Fgf10 and PI3K
downstream targets pAKT and pS6 was unaffected by ablation of Frs2α, but
pErk was down-regulated.
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PI3 kinase may be directly stimulated by the Ras–p110α interac-
tion. In Pten-deficient skin, the epidermal hyperplasia pheno-
type requires two PI3K catalytic subunits, p110α and p110β (25).
Combined deletion of both p110α and p110β was shown to
completely block skin lesions in the absence of Pten. Indeed,
we observed that skin hyperplasia was partially reduced in
Le-Cre;Ptenflox/flox;p110βflox/flox (PtenCKO;p110βCKO) mice and abolished
in Le-Cre;Ptenflox/flox;p110αflox/flox;p110βflox/flox (PtenCKO;p110αCKOβCKO)
animals (Fig. 2A and Fig. S3 A and B). Taking advantage of a
p110α allele (p110αRBD) that contains two point mutations to
disrupt its Ras-binding activity (23), we generated Le-Cre;
Ptenflox/flox;p110αRBD/flox;p110βflox/flox (PtenCKO;p110αRBDβCKO) ani-
mals. Compared with PtenCKO mice, the facial skin in PtenCKO;
p110αRBDβCKO mutants was drastically reduced in thickness, al-
though it was still moderately thicker than PtenCKO;p110αCKOβCKO
mice (Fig. 2A and Fig. S3 A and B). Although PtenCKO;p110αRBDβCKO
skin epidermis still showed elevated levels of pS6 and p4EBP1,
phosphorylation of Erk was reduced to the wild-type level
(Fig. 2B and Fig. S3 A and C). Interestingly, we observed that
Spry4 and Dusp7, two repressors of MAPK signaling, were in-
duced in p110α RBD/flox;p110βflox/flox skin keratinocytes treated
with Pten inhibitor and Cre-expressing adenovirus (Fig. S3 D
and E). This suggests that Ras-independent activation of p110α
may negatively regulate Erk signaling via Spry4 and Dusp7.
Finally, analysis of differentiation and proliferation markers
K14/K10, Ki-67, and ΔNp63 further confirmed that PtenCKO;
p110αCKOβCKO mice were resistant to skin hyperplasia induced
by Pten loss. Immunohistochemistry and Western blot analysis
of PtenCKO;p110αCKOβCKO skin epidermis showed that pAKT,
pS6, and p4EBP1 were reduced compared with those of PtenCKO
samples (Fig. 2B and Fig. S3A). Taken together, these results sug-
gested that Ras signaling directly activates p110α to enhance
PI3K signaling, synergizing with Pten deletion in epidermal
hyperplasia.
The MAPK Pathway Is Vital for Skin Hyperplasia Induced by Pten Loss.
Loss of Pten in keratinocytes has been reported to induce
phosphorylation of Erk, the canonical target of Ras–MAPK
signaling (6, 8). We similarly observed a consistent increase in
the pErk level in PtenCKO skin epidermis, which was abrogated by
deletion of p110α and p110β (Fig. 2B). This raises the possibility
that MAPK signaling may be functionally important in Pten-null
skin tumor. Ras activates the MAPK cascade by initiating the
sequential phosphorylation of Raf, Mek, and Erk kinases, which
ultimately phosphorylate a diverse array of nuclear and cyto-
plasmic substrates (26). Among the three Raf kinase genes in the
mouse genome, Araf is ubiquitously expressed, but it also has the
lowest kinase activity toward Mek (27). On the other hand, Braf
and Craf can form homo- and heterodimers in a Ras-dependent
fashion, which accounts for the majority of Raf kinase activities (26).
In fact, previous studies have shown that ablation of Craf alone was
sufficient to suppress Ras-dependent tumors in the lung and skin
(28, 29). We thus generated Le-Cre;Ptenflox/flox;Braf flox/flox;Crafflox/flox
(PtenCKO;Brff/CrffCKO) animals to ablate Braf and Craf in the
epidermis. Surprisingly, despite of the moderate reduction of
pErk in the epidermis, the skin hyperplasia phenotype was only
modestly mitigated in PtenCKO;Brff/CrffCKO mice (Fig. 3A and
Fig. S4 A–C), suggesting that Braf and Craf were not essential for
Pten-deficient skin hyperplasia.
Studies in mammals have clearly demonstrated that in certain
contexts, Raf could transmit Ras signaling through effectors other
than Mek. Conversely, Mek may also function independently of
Raf kinases and Erk independently of Mek activity (30–32). This
has been supported by phenotypes of various murine Raf, Mek,
and Erk kinase knockouts, which resemble each other in some but
not all developmental processes. To test if the remaining cascade of
the MAPK signaling is still required for skin lesion, we next deleted
Mek and Erk kinases in Le-Cre;Ptenflox/flox;Mek1flox/flox;Mek2KO/KO
(PtenCKOMek1/2CKO) and Le-Cre;Ptenflox/flox;Erk1 KO/KO;Erk2flox/flox
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Fig. 2. Ras signaling enhances PI3K-AKT pathway. (A) Four-week-old PtenCKO and PtenCKO;p110βCKO mice displayed hyperplasia in the epidermis (arrows).
H&E, K14/K10, and Ki-67 staining in the epidermis showed considerable attenuation of hyperplasia phenotype in Pten
CKO;p110αRBDβCKO and PtenCKO;
p110αCKO;βCKO mice. (Scale bars, 50 μm.) (Magnification, Insets: 3×.) (B) Immunoblots of mouse facial skin epidermal layer showed that Fgf10, AKT, and ERK
signaling were reduced in PtenCKO;p110αRBDβCKO and PtenCKO;p110αCKO;βCKO skin epidermis.
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(PtenCKOErk1/2CKO) mice, respectively. Staining for K14/K10
showed a drastic shrinkage in epidermal layers, and Ki-67 and
ΔNp63 indices were indistinguishable from those of WT control
mice (Fig. 3A and Fig. S4 A and B). Notably, deletion of Mek
and Erk did not induce abnormal apoptosis or abrogate the in-
crease in Fgf10, pS6, and p4EBP1 induced by Pten deletion (Fig.
3 and Fig. S4D). Together, these genetic evidence demonstrate
that Ras–MAPK effectors Mek and Erk are required for medi-
ating the Pten–Fgf10–Fgfr signaling axis in skin hyperplasia.
Erk Is a Pharmacological Target Critical for Pten-Null Skin Hyperplaisa.
The striking rescue of the skin hyperplasia phenotype by Erk
deletion prompted us to investigate whether pharmacological
targeting of Erk protein in PtenCKO mice would prevent skin
lesion. Wild-type and PtenCKO mice starting at 3 wk of age were
dosed twice daily by intraperitoneal injection with Erk inhibitor
SCH772984 (25 mg/kg) or vehicle (33). During 2 wk of treatment,
whereas vehicle-treated mice showed rapid emergence of hyper-
plasia, inhibitor-treated animals remained free of lesions (Fig. 4
A–C and Fig. S1B). There was no significant change in body
weight between dosed and vehicle-treated mice, but histological
analysis showed a substantial decrease in skin thickness in treated
mice (Fig. 4 A and B). K14/K10 staining in skin sections from
SCH772984-treated mice also confirmed significant suppression of
epidermal expansion. Compared with vehicle-treated PtenCKO
mice, drug treatment resulted in a substantial reduction in hyper-
proliferative cells as shown by Ki-67 and ΔNp63 staining (Fig. 4 A
and B). Lastly, we treated PtenCKO mice at 5 wk when hyperplasia
was already apparent. After 2 wk of treatment, the skin epidermis
was drastically reduced in thickness, accompanied by dimin-
ished expression of K14/K10, Ki-67, and ΔNp63 (Fig. S5 A–C).
This effect is likely cell autonomous, as we observed that hyper-
proliferation induced by Pten inhibition was similarly suppressed
by addition of Erk inhibitor in mouse keratinocyte cultures (Fig.
S5D). Hence, pharmacological inhibition of Erk signaling could
not only inhibit but also reverse lesion formation in Pten-deficient
epidermis.
Discussion
PTEN deficiency causes skin lesions in PHTS patients and pro-
motes hyperkeratosis and SCC (3–5). Based on our previous
finding that loss of Pten induced FGF signaling in keratinocytes,
we investigated the genetic cascade that led to skin hyperplasia.
Our results showed that epidermal FGF signaling is transmitted
by Frs2α and Shp2, which are required for Ras activation. In
support of the key role of Ras in Pten-deficient lesion, genetic
disruption of the Ras–PI3K interaction or Ras–MAPK pathway
diminished the hyperproliferative effect of Pten loss. Pharma-
cological inhibition of Erk also blocked lesion formation in Pten-
depleted skin (Fig. 4D). These results suggest that FGF signaling
activates the Ras pathway to cooperate with Pten deletion in
skin lesion.
Activation of Ras signaling by the Pten–FGF axis explains a
long-standing conundrum in skin cancer—namely, the mutually
exclusive nature of Ras and Pten mutations in a mouse model of
SCC. In the wild-type skin, DMBA–TPA treatment is known to
predominantly induce H-ras mutations (19). The same treatment
on the skin of Pten+/− mice, however, produced carcinoma that
carried either loss-of-heterozygosity mutations in Pten or acti-
vation mutations in H-ras, but not both. Consistent with this,
transgenic overexpression of activated H-ras did not significantly
enhance malignant transformation of skin tumor generated by
genetic ablation of Pten (8). According to our model of the Pten–
FGF–Ras signaling cascade, deletion of Pten itself is sufficient to
induce Ras signaling in skin epidermis, suggesting that there is
little additional benefit to induce mutation in the H-ras locus. In
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Fig. 3. MAPK pathway activated by Pten–Fgf10 signaling axis is essential for skin hyperplasia. (A) In comparison with PtenCKO mice, the epidermal hyper-
plasia phenotype was moderately reduced in PtenCKO;BrffCrffCKO and completely abolished in PtenCKO;Mek1/2CKO and PtenCKO;Erk1/2CKO mice, as shown by
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contrast, further activation of H-ras in Pten-null skin may even be
counterproductive, as the overall Ras signaling is pushed too
high that it could trigger oncogene-mediated senescence.
Our study suggests that Ras signaling also stimulates PI3K sig-
naling in skin keratinocytes. In Pten-deficient skin lesions, activity
of the PI3K pathway is greatly elevated. Although this originated
from the removal of Pten as the negative regulator of PI3K sig-
naling, it may also involve a positive regulation of PI3K itself to
activate its enzymatic activity (24). The most common mechanism
to stimulate PI3K is through its p85 regulatory subunits, whose
SH2 domains bind a wide variety of cell-surface receptors or
adaptor proteins. In Pten mutant skin, however, our results show
that deletion of PI3K regulatory subunits p85α/β failed to suppress
epidermal hyperplasia. Instead, mutation in the RBD of p110α
strongly reduced the level of pAKT, resulting in significant miti-
gation of the hyperplasia phenotype. This is consistent with a
previous study in mouse embryonic fibroblast cells, which suggests
that direct binding of Ras to the RBD motif of p110α is required
for FGF2 signaling to AKT (23). Furthermore, blocking the Ras
binding region of the p110 alpha subunit also interfered with skin
tumor formation induced by H-Ras and lung adenomas driven by
Kras (34). Notably, deletion of p110β alone also moderately at-
tenuated the Pten epidermal phenotype (25). Although p110β
does not directly interact with Ras, it can be stimulated by Rac1
and Cdc42, two small Rho GTPases downstream to both receptor
tyrosine kinase and G protein-coupled receptor (GPCR) signaling
(35). Given this evidence, our work suggests that FGF-mediated
positive feedback to the PI3K–Akt pathway is an important on-
cogenic mechanism in Pten-deficient skin.
Perturbations in the RAS–MAPK pathway are common in
skin tumors (36). Consistent with previous studies, we observed
that the level of pErk was also elevated in Pten-deficient
keratinocytes (6, 8). Contrary to previous studies that indicated a
crucial role of Craf in Ras-driven lung and skin cancer, we found
that deletion of both Braf and Craf only resulted in modest re-
duction of epidermal hyperplasia (28, 29). Nevertheless, ablation
of either Mek or Erk completely suppressed hyperplasia in
Pten-deficient skin. Importantly, we showed that SCH772984, a
small molecule inhibitor of ERK, was not only effective in pre-
venting epidermal hyperplasia induced by Pten loss; it could also
reverse the hyperplasia phenotype after skin lesions were already
established. Significant efforts are under way to develop phar-
macological inhibitors against the RAS–MAPK pathway, some of
which are already approved for clinical use. Our results suggest that
FGF–Ras signaling can be explored for therapeutic intervention
to treat skin lesions in PHTS and other PTEN-related conditions.
Methods
Mice. Mice carrying Frs2αflox, Shp2flox, p110αflox, p110βflox, p110αRBD (JAX
strain name - B6.129S7(Cg)-Pik3catm1Jdo/J), Erk1KO, Erk2flox, Mek1flox, Mek2KO,
Brafflox, and Crafflox alleles were bred and genotyped as described (23,
37–42). From Lewis Cantley’s laboratory, Weill Cornell Medical College,
New York, we obtained the floxed allele of p85α (Pik3r1) and a knockout
allele of p85β (Pik3r2), two genes that encode the main regulatory subunits
of class IA PI3K, p85α/p55α/p50α and p85β, respectively (43, 44). Le-Cre mice
were kindly provided by Ruth Ashery-Padan, Tel Aviv University, Tel Aviv,
Israel (45). Ptenflox mice were obtained from Jackson Laboratory (46). All
animal experiments were performed according to institutional guidelines
and approved by the Columbia University Institutional Animal Care and
Use Committee (IACUC).
Keratinocyte Culture. Mouse keratinocytes were isolated and cultured from
P0 pups following protocol as described (4). The cells were maintained in
keratinocyte-specific basal media from CELLnTEC. A total of 1 × 105 wild-type
keratinocytes per well were plated in six-well culture plates and treated with
vehicle, Pten inhibitor (VO-OHpic trihydrate; 400 nM), Erk inhibitor (U0126;
10 μM), or both. Total cell count posttreatment was recorded with an auto-
mated cell counter at day 2, 4, 6, and 8 using the Trypan blue dye exclusion test.
Histology and Immunohistochemistry. Briefly, after the mice were euthanized,
skin from the cheek continuing through and around the eyelids were re-
moved and placed in 4% (wt/vol) PFA overnight. The skin samples collected
were either paraffin- or cryo-embedded and sectioned at 8–10-μm thickness.
H&E staining was performed using a Leica Automatic Stainer and immuno-
histochemistry following antigen retrieval in sodium citrate buffer as de-
scribed (47). Antibodies used are Ki-67 (BD Pharmingen; Clone B56; 1:100),
ΔNp63 (Biolegend; Poly6190; 1:500), Keratin 10 (Covance; PRB-159P; 1:200),
Keratin 14 (Thermo Scientific; LL002; 1:100), phospho-4E-BP1(Cell Signaling
Technology; 236B4; 1:500), phospho-S6 (Cell Signaling Technology; D57.2.2E;
1:500), phospho-AktS473 (Cell Signaling Technology; D9E; 1:100), Fgf10 (Milli-
pore; ABN44; 1:100), pErk (Cell Signaling Technology; E10; 1:1000), and Erk
(Santa Cruz; H-72; 1:3000).
K10, K14, Ki-67, and ΔNp63 indices were calculated by counting the
number of positively stained nuclei within 100-μm-long skin tissue sections
and compared with wild-type controls; one-way ANOVA was performed to
determine P value.
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Fig. 4. Pharmacological targeting of Erk prevents
Pten-deficient skin lesion. (A and B) Phenotypic com-
parison of hyperplasia in PtenCKO mice after phar-
macological inhibition of Erk. Administration of Erk
inhibitor SCH772984 or vehicle control in PtenCKO
mice started at 3 wk of age and continued to 5 wk of
age. SCH772984-treated PtenCKO mice showed signif-
icant reduction in skin thickness, keratinocyte pro-
liferation, and differentiation as observed by K14/
K10, Ki-67, and ΔNp63 staining. (Student t test: *P <
0.001; n = 9). (C) Kaplan–Meier curve for PtenCKOmice
treated with inhibitor (red, n = 5) or vehicle (black,
n = 5) only [log rank (Mantel–Cox) test: *P < 0.001;
n = 5]. The appearance of hyperplasia in each ani-
mal was considered as an event toward skin lesion.
(Scale bar, 50 μm.) (Magnification, Insets: 3×.) (D)
Model of Ras-mediated FGF signaling in promoting
epidermal hyperplasia and tumorigenesis in Pten-
deficient skin. Loss of Pten in keratinocytes results
in mTORC1-mediated induction of FGf10 to activate
Fgfr2. This leads to an Frs2–Shp2–Ras signaling
cascade that enhances PI3K signaling and stimu-
lates the Ras–Mek–Erk pathway, both of which are
critical for epidermal hyperplasia and eventual tu-
morigenesis. These skin lesions can be effectively
inhibited by Erk inhibitor SCH772984, suggesting a
therapeutic approach for PHTS.
13160 | www.pnas.org/cgi/doi/10.1073/pnas.1604450113 Mathew et al.
Western Blot. Immediately after mice were euthanized, hair around the face
was removed using Nair hair removal cream. Skin around the cheek and
eyelid area was dissected out in one piece, snap-frozen, and stored at –80 °C
until use. The dissected skin samples were then carefully scraped with a
curette to selectively remove only the epidermal layer. Scrapings were then
lysed in RIPA buffer containing protease inhibitors. Protein concentrations in
the lysates were determined using the BCA kit. Equal amounts of the lysates
were loaded and separated on 10–12% (wt/vol) SDS/PAGE gels before being
transferred onto a PDVF membrane. The blots were stained with primary
antibodies overnight and visualized using IRDye-linked secondary antibody.
Quantitative Real-Time PCR. Total RNA was extracted from skin and kerati-
nocyte samples and converted to cDNA using SuperScriptIII RT kit as de-
scribed (48). Primers used for quantitative PCR analysis are as follows:
Spry2, CAATGGCAGGCAAATGTATG and GGAGGAAGTGAGCAGAGGTG;
Spry4, GCAGCGTCCCTGTGAATCC and TCTGGTCAATGGGTAAGATGGT;
Dusp6, CGTGTGGACCTTGGTGG and ACACGGACAGAACGGATCTC; Dusp7,
GTGCTGCTCTACGACGAGG and TGAAACCACCTTGGAGGTAGT; and Gapdh,
AGGTCGGTGTGAACGGATTTG and TGTAGACCATGTAGTTGAGGTCA.
Inhibitor Treatment. PtenCKO mice were injected intraperitoneally with
SCH772984 (Chemitek) at a 25-mg/kg dosage twice daily or with vehicle con-
trol for a period of 14 d as described (33, 49). A SCH772984 stock solution of
10mg/mL was prepared by dissolving 11.9 mg SCH772984 in 986 μL 20% hydroxy
propyl β cyclodextrin and 14.3 μL 2N NaOH, followed by continuous vortexing/
sonication for 5 min and pH adjustment to 4.5. Before dosing, SCH772984 so-
lution was brought to room temperature (∼30 min). The mice were moni-
tored daily for changes in hyperplasia phenotype, and facial epidermal tissue was
harvested and used for histological analysis after the trial period.
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